Prs10 - Population Health Impact of Omalizumab Over 11 Years of Use in Ireland in Moderate to Severe Allergic Asthma

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2404
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Effect of Omalizumab on Lung Function and Eosinophil Levels in Adolescents With Moderate-To-Severe Allergic Asthma

Annals of Allergy, Asthma and Immunology
Respiratory MedicinePulmonaryAllergyImmunology
2020English

Lengthening Omalizumab Dosing Interval in Treatment of Moderate to Severe Persistent Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Omalizumab in the Treatment of Severe Allergic (IgE-mediated) Asthma: An Update on Recent Developments

Clinical and Translational Allergy
ImmunologyPulmonaryAllergyRespiratory Medicine
2013English

Omalizumab Reduced Inhaled Corticosteroid Use and Exacerbations in Childhood Allergic Asthma

Evidence-Based Medicine
Medicine
2002English

A Randomized, Open-Label, Parallel-Group Clinical Study to Evaluate the Efficacy and Safety of Omalizumab in the Treatment of Persistent Moderate and Severe Allergic Asthma and Persistent Allergic Rhinitis in Pediatric Patients 6 to 17 Years of Age

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Real-Life Effectiveness of Omalizumab in Severe Allergic Asthma Above the Recommended Dosing Range Criteria

Pediatrics
Child HealthPediatricsPerinatology
2017English

Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma

Journal of Managed Care Pharmacy
2005English

Effects of Omalizumab on Blood Eosinophil Numbers in Patients With Allergic Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

ABS37: Add-On Omalizumab Improves Asthma Control Across Multiple Measures of Response in Patients With Severe Persistent Allergic (IgE-mediated) Asthma

Primary Care Respiratory Journal
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy